Now Reading: GLP-1 therapies target heart, kidney risks in diabetes
-
01
GLP-1 therapies target heart, kidney risks in diabetes
India's diabetes care is shifting beyond blood sugar control as GLP-1 receptor agonists show promise in protecting heart and kidney health. With over 100 million adults living with type 2 diabetes, a…
The Story in Brief
India's diabetes care is shifting beyond blood sugar control as GLP-1 receptor agonists show promise in protecting heart and kidney health. With over 100 million adults living with type 2 diabetes, a number that could cross 150 million by 2050, according to the International Diabetes Federation, experts say modern treatment must address obesity, cardiovascular risk, and kidney complications. The World Health Organization added GLP-1 therapies to its Essential Medicines List in 2025 for high-risk patients. However, Hindustan Times reports that a monthly cost of Rs 1,300-1,500 remains unaffordable for most Indian families. The newspaper's opinion piece, by former IAS officer Indu Bhushan, calls for a phased, four- or five-state pilot programme targeting patients with diabetes plus heart or kidney disease, with safeguards against inappropriate use and high dropout rates.
The Indian Opinion
The hype around GLP-1 drugs as a magic bullet for India's diabetes epidemic ignores two hard realities: cost and adherence. At Rs 1,300-1,500 a month, these medicines are out of reach for most households, and international studies show high discontinuation rates. The real test lies not in clinical trial results but in whether a phased government programme can deliver consistent outcomes under Indian conditions. Will the four- or five-state pilot produce the evidence needed before a national rollout?
Sources (2): timesnownews.com, hindustantimes.com
This story was synthesised by AI from the 2 sources linked above.
Updated: this story now draws on 2 sources.
